Repligen Co. (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 1,932 shares of the stock in a transaction dated Wednesday, June 6th. The stock was sold at an average price of $44.31, for a total transaction of $85,606.92. Following the transaction, the director now owns 7,354 shares in the company, valued at $325,855.74. The sale was disclosed in a filing with the SEC, which is available through this link.

RGEN traded up $0.31 on Thursday, hitting $44.78. 247,400 shares of the company’s stock were exchanged, compared to its average volume of 282,254. Repligen Co. has a fifty-two week low of $29.56 and a fifty-two week high of $46.81. The company has a quick ratio of 10.25, a current ratio of 12.22 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.94 billion, a PE ratio of 64.90, a price-to-earnings-growth ratio of 2.96 and a beta of 0.90.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.15 by $0.02. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.88 million. During the same quarter in the previous year, the firm earned $0.15 EPS. The company’s quarterly revenue was up 46.4% compared to the same quarter last year. research analysts anticipate that Repligen Co. will post 0.7 earnings per share for the current year.

RGEN has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, May 26th. TheStreet raised shares of Repligen from a “c” rating to a “b-” rating in a research report on Tuesday, March 13th. Finally, BidaskClub raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Repligen presently has an average rating of “Buy” and an average price target of $44.88.

A number of institutional investors and hedge funds have recently modified their holdings of RGEN. Victory Capital Management Inc. raised its holdings in Repligen by 38.9% in the 1st quarter. Victory Capital Management Inc. now owns 5,755 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 1,612 shares during the period. Budros Ruhlin & Roe Inc. purchased a new stake in Repligen during the first quarter worth about $220,000. Bayesian Capital Management LP purchased a new stake in Repligen during the first quarter worth about $228,000. Profund Advisors LLC increased its stake in Repligen by 29.2% during the first quarter. Profund Advisors LLC now owns 7,174 shares of the biotechnology company’s stock worth $260,000 after purchasing an additional 1,620 shares during the period. Finally, Xact Kapitalforvaltning AB purchased a new stake in Repligen during the first quarter worth about $269,000. Hedge funds and other institutional investors own 87.49% of the company’s stock.

About Repligen

Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.